E Fund Management Co. Ltd. Cuts Position in ADMA Biologics Inc $ADMA

Key Points

• E Fund Management Co. Ltd. has reduced its stake in ADMA Biologics Inc. by 42.8%, selling 15,597 shares and now holding 20,872 shares valued at $414,000.
• ADMA Biologics saw an increase in institutional investment, with Farther Finance Advisors LLC boosting its stake by over 1,149% during the first quarter.
• Analyst ratings for ADMA Biologics have fluctuated, with Raymond James raising its price target from $25 to $32, while Wall Street Zen downgraded the stock from "hold" to "sell."

E Fund Management Co. Ltd. lowered its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 42.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,872 shares of the biotechnology company's stock after selling 15,597 shares during the quarter. E Fund Management Co. Ltd.'s holdings in ADMA Biologics were worth $414,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ADMA. Cetera Investment Advisers boosted its stake in shares of ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after purchasing an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ADMA Biologics by 1.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after purchasing an additional 711 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of ADMA Biologics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after purchasing an additional 746 shares during the last quarter. GF Fund Management CO. LTD. boosted its stake in shares of ADMA Biologics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock valued at $120,000 after purchasing an additional 1,089 shares during the last quarter. Finally, Journey Strategic Wealth LLC boosted its stake in shares of ADMA Biologics by 6.6% in the 1st quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock valued at $354,000 after purchasing an additional 1,102 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on ADMA shares. Raymond James Financial raised their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen downgraded ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $27.67.

Insider Buying and Selling

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of ADMA Biologics stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the sale, the director directly owned 94,830 shares in the company, valued at $1,987,636.80. This trade represents a 17.42% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by corporate insiders.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA traded down $0.2150 on Tuesday, hitting $17.4150. The company's stock had a trading volume of 1,366,850 shares, compared to its average volume of 3,141,271. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The company has a market capitalization of $4.16 billion, a PE ratio of 20.31 and a beta of 0.38. The company has a 50-day simple moving average of $18.22 and a 200 day simple moving average of $18.88. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm's revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.13 earnings per share. Sell-side analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.